<DOC>
	<DOCNO>NCT01812707</DOCNO>
	<brief_summary>Alirocumab ( SAR236553/REGN727 ) fully human monoclonal antibody bind proprotein convertase subtilisin/kexin type 9 ( PCSK9 ) . Primary Objective study : To evaluate effect alirocumab low-density lipoprotein cholesterol ( LDL-C ) level 12 week treatment comparison placebo participant LDL-C ≥100 mg/dL ( ≥2.59 mmol/L ) ongoing stable atorvastatin therapy . Secondary Objectives : - To evaluate effect alirocumab lipid level 12 week treatment comparison placebo - To evaluate safety tolerability alirocumab - To evaluate development anti-alirocumab antibody - To evaluate pharmacokinetics alirocumab</brief_summary>
	<brief_title>Efficacy Safety Evaluation Alirocumab ( SAR236553/REGN727 ) Patients With Primary Hypercholesterolemia Stable Atorvastatin Therapy Japan</brief_title>
	<detailed_description>The duration study participation depend status participant screening : 21 27 week include screening/run-in period 1 7 week , double-blind treatment period 12 week , follow 8-week follow-up period .</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Inclusion criterion : Participants primary hypercholesterolemia treat atorvastatin stable dose 520 mg least 6 week prior screen likely LDLC ≥100 mg/dL ( ≥2.59 mmol/L ) screen visit . OR Participants primary hypercholesterolemia receive lipidlowering treatment atorvastatin , stable dose atorvastatin 520 mg least 6 week prior screen likely LDLC ≥100 mg/dL ( ≥2.59 mmol/L ) 6week runin treatment period atorvastatin therapy . Exclusion criterion : 1 . LDLC &lt; 100 mg/dL ( &lt; 2.59 mmol/L ) screen visit participant treat stable dose atorvastatin 520 mg least 6 week prior screen OR end 6week runin period atorvastatin participant receive lipid lower treatment atorvastatin , stable dose atorvastatin 520 mg least 6 week prior screen 2 . Participants type 1 diabetes 3 . Participants type 2 diabetes treat insulin , without , consider poorly control screening . The information intend contain consideration relevant participant 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>